The <i>Chlamydia</i> protein CpoS modulates the inclusion microenvironment and restricts the interferon response by acting on Rab35 — Karsten Meier (2022) | RDL Network
The <i>Chlamydia</i> protein CpoS modulates the inclusion microenvironment and restricts the interferon response by acting on Rab35
Preprint 2022 en
Authors
KM
Karsten Meier
LJ
Lana H. Jachmann
LP
Lucía Peña‐Pérez
Abstract
1 min read
ABSTRACT The obligate intracellular bacterium Chlamydia trachomatis inserts into the membrane of its vacuole (the inclusion) a family of poorly characterized Inc proteins. While the Inc CpoS was recently revealed as a critical suppressor of host cellular immune surveillance, the underlying mechanism remained unknown. By complementing a cpoS mutant with modified variants of CpoS, we found that CpoS blocks distinct cellular defense responses through distinct mechanisms. Specifically, we show that the ability of CpoS to interact with Rab GTPases is not only instrumental to its ability to mediate lipid transport to the inclusion, but also key to CpoS-mediated inhibition of type I interferon responses. Indeed, depletion of Rab35 can phenocopy the respective defect of the cpoS mutant. Unexpectedly, we found that CpoS is also essential for the formation of inclusion microdomains that control the spatial organization of multiple Incs involved in signaling and modulation of the host cellular cytoskeleton. Overall, our findings highlight the modulation of membrane trafficking as a pathogenic immune evasion strategy and the role of Inc-Inc interactions in shaping the inclusion microenvironment.
Karsten Meier, Lana H. Jachmann, Gözde Türköz, Mohammed Rizwan Babu Sait, Lucía Peña‐Pérez, Oliver Kepp, Raphael H. Valdivia, Guido Guido Kroemer, Barbara S. Sixt
Minyu Wang, Soroor Hediyeh Zadeh, Angela Pizzolla, Kevin Thia, David Gyorki, Grant A. McArthur, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Miles C. Andrews, George Au‐Yeung, Ali Weppler, Shahneen Sandhu, Joseph A. Trapani, Melissa J. Davis, Paul J. Neeson
Discussion(0)
No comments yet. Be the first to comment.